felodipine has been researched along with Heart Failure in 61 studies
Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.
felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The echocardiographic substudy of the Vasodilator-Heart Failure Trial III (V-HeFT III) aimed to determine if felodipine treatment in patients with heart failure who were taking an angiotensin-converting enzyme inhibitor had a favorable effect on left ventricular (LV) structure and function." | 9.09 | Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change. ( Baruch, L; Cohen, IS; Cohn, JN; Deedwania, P; Germanson, T; Lopez, B; Perry, G; Taylor, WR; Wong, M, 2000) |
| "Four hundred fifty men with left ventricular (LV) systolic dysfunction were administered standard heart failure treatment and felodipine extended release (ER) or placebo in the Vasodilator Heart Failure Trial III (V-HeFT III)." | 9.09 | Plasma norepinephrine and atrial natriuretic peptide in heart failure: influence of felodipine in the third Vasodilator Heart Failure Trial. V-HeFT III investigators. ( Anand, IS; Cohn, JN; Germanson, T; Judd, D; Smith, RF; Taylor, WR; Wong, M; Ziesche, S, 2000) |
| "To compare the effects of felodipine and placebo in patients with New York Heart Association functional class II or III and stable congestive heart failure despite treatment with an angiotensin converting enzyme inhibitor, diuretic, or digoxin, or any combination of these three drugs." | 9.08 | Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group. ( Littler, WA; Sheridan, DJ, 1995) |
| "In congestive heart failure patients the kinetics of felodipine, a dihydropyridine calcium antagonist, show interpatient differences after acute i." | 9.08 | Relationship of changes in felodipine pharmacokinetics to haemodynamics during chronic oral treatment of congestive heart failure patients. ( Dunselman, PH; Scaf, AH; Wesseling, H, 1995) |
| "Felodipine exerts a well-tolerated additional sustained vasodilator effect in patients with heart failure treated with enalapril, but the only possible long-term benefit was a trend for better exercise tolerance and less depression of quality of life in the second year of treatment." | 9.08 | Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. ( Anand, I; Baruch, L; Boden, W; Cintron, G; Cohn, JN; Dunkman, WB; Loeb, H; Loss, L; Rochin, P; Smith, R; Ziesche, S, 1997) |
| "Twenty patients on conventional therapy for severe congestive heart failure (CHF) were randomly assigned to adjunctive treatment with felodipine (n = 10) or placebo (n = 10) and followed over a 6-month period." | 9.06 | Long-term clinical, hemodynamic, angiographic, and neurohumoral responses to vasodilation with felodipine in patients with chronic congestive heart failure. ( Amtorp, O; Kassis, E, 1990) |
| "The efficacy of felodipine, a vasodilating calcium antagonist, was analysed in 23 patients with congestive heart failure, New York Heart Association class III, during an 8-week, double-blind, randomized, placebo-controlled, parallel study." | 9.06 | Efficacy of felodipine in congestive heart failure. ( Dunselman, PH; Hamer, JP; Kuntze, CE; Lie, KI; Scaf, AH; van Bruggen, A; Wessling, H, 1989) |
| "A vascular selective calcium antagonist, felodipine, was evaluated in a randomised, double blind, crossover trial in 18 patients with chronic congestive heart failure of ischaemic cause." | 9.06 | Efficacy of felodipine in chronic congestive heart failure: a placebo controlled haemodynamic study at rest and during exercise and orthostatic stress. ( Amtorp, O; Fritz-Hansen, P; Kassis, E; Waldorff, S, 1987) |
| "Previous open studies have suggested that felodipine, a selective calcium antagonist and vasodilator, may be useful in the treatment of heart failure." | 9.06 | Felodipine in patients with chronic heart failure: discrepant haemodynamic and clinical effects. ( Littler, WA; Murray, RG; Tan, LB, 1987) |
| "A possible interaction between felodipine and digoxin was studied in 23 patients with congestive heart failure before and after 8 weeks treatment with both drugs." | 9.06 | Digoxin-felodipine interaction in patients with congestive heart failure. ( Dunselman, PH; Kuntze, CE; Lie, KI; Scaf, AH; Wesseling, H, 1988) |
| "The pharmacodynamics of felodipine were analyzed in patients with congestive heart failure in a randomized, double-blind, placebo-controlled study." | 9.06 | Plasma concentration-effect relationship of felodipine intravenously in patients with congestive heart failure. ( Dunselman, PH; Edgar, B; Kuntze, CE; Lie, KI; Scaf, AH; van Bruggen, A; Wesseling, H, 1989) |
| " In a randomized, parallel, double-blind study felodipine was administered to 11 and placebo to 12 patients with congestive heart failure." | 9.06 | Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure. ( Dunselman, PH; Edgar, B; Kuntze, CE; Scaf, AH; Wesseling, H, 1989) |
| "The interaction between felodipine and digoxin was studied after a single oral dose and at steady state in 14 patients with congestive heart failure." | 9.06 | Effects of felodipine on plasma digoxin levels and haemodynamics in patients with heart failure. ( Aberg, J; Kirch, W; Laskowski, M; Ohnhaus, EE, 1989) |
| "We sought to characterize the effects of the nonselective Ca2+ channel antagonist, verapamil, and the vascular-selective Ca2+ channel antagonist, felodipine, on obese, hypertensive, heart failure-prone, female SHHF/Mcc-fa(cp) rats." | 7.69 | Verapamil accelerates the transition to heart failure in obese, hypertensive, female SHHF/Mcc-fa(cp) rats. ( Altschuld, RA; Hensley, J; Hoepf, TM; Hohl, CM; McCune, SA; Park, S; Radin, MJ, 1997) |
| "We studied the effects of a dihydropyridine calcium blocker, felodipine, on left ventricular (LV) contractile performance and diastolic filling dynamics in conscious dogs with pacing-induced congestive heart failure (CHF) before and after autonomic blockade." | 7.69 | Effects of felodipine on left ventricular systolic and diastolic performance in congestive heart failure. ( Cheng, CP; Little, WC; Pettersson, K, 1994) |
| "In order to assess the effects of dihydropyridine calcium antagonist on sympathetic nerve activity (SNA) in experimental chronic heart failure (CHF), felodipine was given to rats with CHF induced by coronary artery ligation." | 7.69 | Effects of calcium antagonist felodipine on renal sympathetic nerve activity in rats with congestive heart failure. ( Hedner, T; Sun, X; Thorén, P; Zhang, W; Zhao, X, 1997) |
| "1 mg/kg oral felodipine in 12 men with heart failure due to ischaemic heart disease aged 37-72 y." | 7.68 | Central and peripheral haemodynamic responses to felodipine in congestive heart failure. ( Capewell, S; Muir, AL; Wathen, CG, 1991) |
| " The combination of nitrendipine plus enalapril was also examined in ischemic failure and in rats with spontaneous hypertension." | 7.67 | Enalapril in experimental hypertension and acute heart failure: comparison with calcium channel blockers. ( Adkins, E; Emmert, S; Ludden, CT; Ribeiro, LG; Seymour, AA; Sweet, CS, 1986) |
| "The acute and long term central haemodynamic effects of felodipine were studied in 9 patients with severe congestive heart failure (NYHA III-IV)." | 7.67 | Haemodynamic effects of felodipine in congestive heart failure. ( Held, P; Swedberg, K, 1987) |
| "In order to assess the effect of felodipine, a new calcium antagonist with vascular selectivity, on regional blood flow distribution at rest in chronic congestive heart failure, ten patients were studied during an acute test." | 7.67 | Felodipine in severe chronic congestive heart failure: acute effects on central hemodynamics and regional blood flow distribution. ( Binetti, G; Cervi, V; Ferretti, RM; Magnani, B; Rubino, I; Spadoni, R; Varani, E, 1989) |
| " The efficacy of felodipine a new calcium channel blocker with selective vasodilator activity in the management of severe low output cardiac failure, secondary to coronary heart disease, was determined in 10 patients." | 7.67 | Sustained haemodynamic effects of felodipine in patients with chronic cardiac failure. ( Hutton, I; Martin, W; McGhie, AI; Tweddel, AC, 1988) |
| "The hemodynamic effects of increasing dosages of felodipine, a new calcium antagonist with selective vasodilator properties, were studied in 13 patients with chronic cardiac failure." | 7.67 | Hemodynamic effects of felodipine in congestive heart failure. ( Binetti, G; Branzi, A; Ferretti, RM; Giovanelli, N; Magnani, B; Negroni, S; Pancaldi, S; Specchia, S, 1987) |
| "Felodipine is a second-generation dihydropyridine calcium antagonist with a high degree of vascular selectivity which, in the doses used in this study, exerts its systemic arterial effect by decreasing peripheral vascular resistance without producing negative inotropic effects." | 6.68 | Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators. ( Boden, WE; Carson, PE; Cohn, JN; Conrad, CH; Syat, D; Ziesche, S, 1996) |
| "In 13 patients with congestive heart failure we tested the acute hemodynamic effects of 5 vs." | 6.67 | Acute and chronic efficacy of felodipine in congestive heart failure. ( Agostoni, P; Doria, E; Polese, A; Riva, S, 1991) |
| "Studies in patients with congestive heart failure (CHF) have demonstrated an abnormal beta-adrenergic reflex vasodilation during orthostatic tilt." | 6.66 | Cardiovascular and neurohumoral postural responses and baroreceptor abnormalities during a course of adjunctive vasodilator therapy with felodipine for congestive heart failure. ( Amtorp, O; Kassis, E, 1987) |
| "Felodipine is a new dihydropyridine calcium antagonist drug with cardiovascular effects, whose pharmacokinetics and effects on plasma digoxin levels have been studied in patients with left ventricular failure." | 6.66 | Pharmacokinetics of felodipine and effect on digoxin plasma levels in patients with heart failure. ( Billing, E; Lundman, T; Moberg, L; Olsson, G; Rehnqvist, N, 1987) |
| "The chemistry, pharmacology, pharmacokinetics, clinical uses, adverse effects, and dosage of felodipine and isradipine are reviewed." | 6.38 | Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension. ( Symes, LR; Walton, T, 1993) |
| "Felodipine, a dihydropyridine calcium-channel antagonist, significantly reduces systolic and diastolic blood pressure (BP) in patients with hypertension and has been associated with beneficial hemodynamic effects in patients with chronic stable angina pectoris or congestive heart failure (CHF)." | 6.16 | Felodipine: a new dihydropyridine calcium-channel antagonist. ( Lopez, LM; Yedinak, KC, 1991) |
| "Peak and trough concentrations after 8 weeks oral therapy with felodipine, a vasodilating calcium antagonist of the dihydropyridine group, were predicted from intravenous pharmacokinetic data before therapy in 11 patients, randomly allocated to felodipine treatment 10 mg b." | 5.28 | Oral pharmacokinetics of felodipine in patients with congestive heart failure: variable prediction using intravenous data. ( Dunselman, PH; Scaf, AH; Wesseling, H, 1989) |
| "Felodipine is a new calcium antagonist with a high degree of vascular selectivity." | 5.27 | Acute haemodynamic and metabolic effects of felodipine in congestive heart failure. ( Campbell, S; Jewitt, DE; Monaghan, MJ; Timmis, AD; Walker, L, 1984) |
| "Its potential role in the treatment of congestive heart failure was examined in short and long term oral studies." | 5.27 | Studies with felodipine in congestive heart failure. ( Jewitt, DE; Timmis, AD, 1985) |
| "Four hundred fifty men with left ventricular (LV) systolic dysfunction were administered standard heart failure treatment and felodipine extended release (ER) or placebo in the Vasodilator Heart Failure Trial III (V-HeFT III)." | 5.09 | Plasma norepinephrine and atrial natriuretic peptide in heart failure: influence of felodipine in the third Vasodilator Heart Failure Trial. V-HeFT III investigators. ( Anand, IS; Cohn, JN; Germanson, T; Judd, D; Smith, RF; Taylor, WR; Wong, M; Ziesche, S, 2000) |
| "The echocardiographic substudy of the Vasodilator-Heart Failure Trial III (V-HeFT III) aimed to determine if felodipine treatment in patients with heart failure who were taking an angiotensin-converting enzyme inhibitor had a favorable effect on left ventricular (LV) structure and function." | 5.09 | Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change. ( Baruch, L; Cohen, IS; Cohn, JN; Deedwania, P; Germanson, T; Lopez, B; Perry, G; Taylor, WR; Wong, M, 2000) |
| "To compare the effects of felodipine and placebo in patients with New York Heart Association functional class II or III and stable congestive heart failure despite treatment with an angiotensin converting enzyme inhibitor, diuretic, or digoxin, or any combination of these three drugs." | 5.08 | Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group. ( Littler, WA; Sheridan, DJ, 1995) |
| "Felodipine exerts a well-tolerated additional sustained vasodilator effect in patients with heart failure treated with enalapril, but the only possible long-term benefit was a trend for better exercise tolerance and less depression of quality of life in the second year of treatment." | 5.08 | Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. ( Anand, I; Baruch, L; Boden, W; Cintron, G; Cohn, JN; Dunkman, WB; Loeb, H; Loss, L; Rochin, P; Smith, R; Ziesche, S, 1997) |
| "In congestive heart failure patients the kinetics of felodipine, a dihydropyridine calcium antagonist, show interpatient differences after acute i." | 5.08 | Relationship of changes in felodipine pharmacokinetics to haemodynamics during chronic oral treatment of congestive heart failure patients. ( Dunselman, PH; Scaf, AH; Wesseling, H, 1995) |
| "The interaction between felodipine and digoxin was studied after a single oral dose and at steady state in 14 patients with congestive heart failure." | 5.06 | Effects of felodipine on plasma digoxin levels and haemodynamics in patients with heart failure. ( Aberg, J; Kirch, W; Laskowski, M; Ohnhaus, EE, 1989) |
| "The efficacy of felodipine, a vasodilating calcium antagonist, was analysed in 23 patients with congestive heart failure, New York Heart Association class III, during an 8-week, double-blind, randomized, placebo-controlled, parallel study." | 5.06 | Efficacy of felodipine in congestive heart failure. ( Dunselman, PH; Hamer, JP; Kuntze, CE; Lie, KI; Scaf, AH; van Bruggen, A; Wessling, H, 1989) |
| "The pharmacodynamics of felodipine were analyzed in patients with congestive heart failure in a randomized, double-blind, placebo-controlled study." | 5.06 | Plasma concentration-effect relationship of felodipine intravenously in patients with congestive heart failure. ( Dunselman, PH; Edgar, B; Kuntze, CE; Lie, KI; Scaf, AH; van Bruggen, A; Wesseling, H, 1989) |
| " In a randomized, parallel, double-blind study felodipine was administered to 11 and placebo to 12 patients with congestive heart failure." | 5.06 | Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure. ( Dunselman, PH; Edgar, B; Kuntze, CE; Scaf, AH; Wesseling, H, 1989) |
| "A possible interaction between felodipine and digoxin was studied in 23 patients with congestive heart failure before and after 8 weeks treatment with both drugs." | 5.06 | Digoxin-felodipine interaction in patients with congestive heart failure. ( Dunselman, PH; Kuntze, CE; Lie, KI; Scaf, AH; Wesseling, H, 1988) |
| "Previous open studies have suggested that felodipine, a selective calcium antagonist and vasodilator, may be useful in the treatment of heart failure." | 5.06 | Felodipine in patients with chronic heart failure: discrepant haemodynamic and clinical effects. ( Littler, WA; Murray, RG; Tan, LB, 1987) |
| " In a double-blind crossover comparative study of the effects of felodipine versus placebo in 10 patients with heart failure in NYHA class III, all patients decreased systemic vascular resistance (SVR) and increased cardiac index (CI), not only at rest but also during exercise." | 5.06 | Arterial vasodilator therapy in heart failure: haemodynamic response patterns predictive of changes in exercise capacity. ( Fox, Y; Littler, WA; Tan, LB, 1989) |
| "A vascular selective calcium antagonist, felodipine, was evaluated in a randomised, double blind, crossover trial in 18 patients with chronic congestive heart failure of ischaemic cause." | 5.06 | Efficacy of felodipine in chronic congestive heart failure: a placebo controlled haemodynamic study at rest and during exercise and orthostatic stress. ( Amtorp, O; Fritz-Hansen, P; Kassis, E; Waldorff, S, 1987) |
| "Twenty patients on conventional therapy for severe congestive heart failure (CHF) were randomly assigned to adjunctive treatment with felodipine (n = 10) or placebo (n = 10) and followed over a 6-month period." | 5.06 | Long-term clinical, hemodynamic, angiographic, and neurohumoral responses to vasodilation with felodipine in patients with chronic congestive heart failure. ( Amtorp, O; Kassis, E, 1990) |
| "A recently proposed analytical technique to determine whether an inotropic agent improves cardiac pumping performance via its vasodilatory or its positive inotropic effects was adopted to evaluate the pharmacological properties of a positive inotropic agent, dobutamine, and a vasodilatory calcium antagonist, felodipine, in patients with severe heart failure." | 5.06 | An analytical method to separate inotropic and vasodilatory drug effects in patients with heart failure. ( Littler, WA; Murray, RG; Tan, LB, 1987) |
| "Felodipine is a vascular-selective, dihydropyridine calcium antagonist previously investigated as a conventional tablet formulation administered twice daily." | 3.77 | Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. ( Faulds, D; Todd, PA, 1992) |
| "In order to assess the effects of dihydropyridine calcium antagonist on sympathetic nerve activity (SNA) in experimental chronic heart failure (CHF), felodipine was given to rats with CHF induced by coronary artery ligation." | 3.69 | Effects of calcium antagonist felodipine on renal sympathetic nerve activity in rats with congestive heart failure. ( Hedner, T; Sun, X; Thorén, P; Zhang, W; Zhao, X, 1997) |
| "We sought to characterize the effects of the nonselective Ca2+ channel antagonist, verapamil, and the vascular-selective Ca2+ channel antagonist, felodipine, on obese, hypertensive, heart failure-prone, female SHHF/Mcc-fa(cp) rats." | 3.69 | Verapamil accelerates the transition to heart failure in obese, hypertensive, female SHHF/Mcc-fa(cp) rats. ( Altschuld, RA; Hensley, J; Hoepf, TM; Hohl, CM; McCune, SA; Park, S; Radin, MJ, 1997) |
| "We studied the effects of a dihydropyridine calcium blocker, felodipine, on left ventricular (LV) contractile performance and diastolic filling dynamics in conscious dogs with pacing-induced congestive heart failure (CHF) before and after autonomic blockade." | 3.69 | Effects of felodipine on left ventricular systolic and diastolic performance in congestive heart failure. ( Cheng, CP; Little, WC; Pettersson, K, 1994) |
| "1 mg/kg oral felodipine in 12 men with heart failure due to ischaemic heart disease aged 37-72 y." | 3.68 | Central and peripheral haemodynamic responses to felodipine in congestive heart failure. ( Capewell, S; Muir, AL; Wathen, CG, 1991) |
| " In patients with congestive cardiac failure, the calcium channel blocker, felodipine, causes a marked reduction in systemic vascular resistance and left ventricular filling pressures, but venous volume remains unchanged." | 3.68 | Modulation of venous tone in heart failure. ( Muir, AL; Nolan, J, 1991) |
| " The efficacy of felodipine a new calcium channel blocker with selective vasodilator activity in the management of severe low output cardiac failure, secondary to coronary heart disease, was determined in 10 patients." | 3.67 | Sustained haemodynamic effects of felodipine in patients with chronic cardiac failure. ( Hutton, I; Martin, W; McGhie, AI; Tweddel, AC, 1988) |
| "In order to assess the effect of felodipine, a new calcium antagonist with vascular selectivity, on regional blood flow distribution at rest in chronic congestive heart failure, ten patients were studied during an acute test." | 3.67 | Felodipine in severe chronic congestive heart failure: acute effects on central hemodynamics and regional blood flow distribution. ( Binetti, G; Cervi, V; Ferretti, RM; Magnani, B; Rubino, I; Spadoni, R; Varani, E, 1989) |
| "The acute and long term central haemodynamic effects of felodipine were studied in 9 patients with severe congestive heart failure (NYHA III-IV)." | 3.67 | Haemodynamic effects of felodipine in congestive heart failure. ( Held, P; Swedberg, K, 1987) |
| " The combination of nitrendipine plus enalapril was also examined in ischemic failure and in rats with spontaneous hypertension." | 3.67 | Enalapril in experimental hypertension and acute heart failure: comparison with calcium channel blockers. ( Adkins, E; Emmert, S; Ludden, CT; Ribeiro, LG; Seymour, AA; Sweet, CS, 1986) |
| "The hemodynamic effects of increasing dosages of felodipine, a new calcium antagonist with selective vasodilator properties, were studied in 13 patients with chronic cardiac failure." | 3.67 | Hemodynamic effects of felodipine in congestive heart failure. ( Binetti, G; Branzi, A; Ferretti, RM; Giovanelli, N; Magnani, B; Negroni, S; Pancaldi, S; Specchia, S, 1987) |
| "The systemic and coronary haemodynamic effects of felodipine were evaluated at rest and during stress induced atrial pacing in fourteen patients with chronic cardiac failure, secondary to coronary heart disease." | 3.67 | Felodipine in ventricular dysfunction. ( Hutton, I; Tweddel, AC, 1986) |
| "Felodipine is a second-generation dihydropyridine calcium antagonist with a high degree of vascular selectivity which, in the doses used in this study, exerts its systemic arterial effect by decreasing peripheral vascular resistance without producing negative inotropic effects." | 2.68 | Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators. ( Boden, WE; Carson, PE; Cohn, JN; Conrad, CH; Syat, D; Ziesche, S, 1996) |
| "In 13 patients with congestive heart failure we tested the acute hemodynamic effects of 5 vs." | 2.67 | Acute and chronic efficacy of felodipine in congestive heart failure. ( Agostoni, P; Doria, E; Polese, A; Riva, S, 1991) |
| "Studies in patients with congestive heart failure (CHF) have demonstrated an abnormal beta-adrenergic reflex vasodilation during orthostatic tilt." | 2.66 | Cardiovascular and neurohumoral postural responses and baroreceptor abnormalities during a course of adjunctive vasodilator therapy with felodipine for congestive heart failure. ( Amtorp, O; Kassis, E, 1987) |
| "In conclusion, in patients with chronic cardiac failure, treatment with a calcium channel blocker produced sustained haemodynamic improvement, particularly on exercise, and combination with nitrate produced further benefit." | 2.66 | Calcium channel blocker and isosorbide 5-mononitrate in the management of chronic cardiac failure. ( Hutton, I; Martin, W; McGhie, AI; Tweddel, AC, 1987) |
| "Felodipine is a new dihydropyridine calcium antagonist drug with cardiovascular effects, whose pharmacokinetics and effects on plasma digoxin levels have been studied in patients with left ventricular failure." | 2.66 | Pharmacokinetics of felodipine and effect on digoxin plasma levels in patients with heart failure. ( Billing, E; Lundman, T; Moberg, L; Olsson, G; Rehnqvist, N, 1987) |
| "Felodipine is a highly vascular selective calcium entry blocker, with a vascular selectivity ratio greater than 100, as shown experimentally." | 2.39 | Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine. ( Cheng, CP; Elvelin, L; Little, WC; Nordlander, M, 1995) |
| "The history of the treatment of heart failure may be divided into three stages, the consequences of different conceptions of the physiopathology of the disease, with diuretics to counteract salt and water retention, vasodilators to improve conditions of cardiac load, angiotensin converting enzyme inhibitors to limit the effect of neurotumoral and sympathetic activation." | 2.39 | [Calcium antagonists and treatment of chronic heart failure]. ( Lanfranchi, J, 1995) |
| "The chemistry, pharmacology, pharmacokinetics, clinical uses, adverse effects, and dosage of felodipine and isradipine are reviewed." | 2.38 | Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension. ( Symes, LR; Walton, T, 1993) |
| "Diastolic dysfunction and left ventricular hypertrophy are also associated with a higher risk of heart failure and systolic dysfunction." | 1.30 | [Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach]. ( Anguita Sánchez, M, 1999) |
| "Heart failure is today one of the most serious health problems of modern industrialized societies." | 1.29 | [The role of ACE inhibitors in heart failure. Lessons of CONSENSUS, SOLVD and V-HeFTII]. ( Dessì-Fulgheri, P; Paci, MV; Rappelli, A, 1994) |
| "Peak and trough concentrations after 8 weeks oral therapy with felodipine, a vasodilating calcium antagonist of the dihydropyridine group, were predicted from intravenous pharmacokinetic data before therapy in 11 patients, randomly allocated to felodipine treatment 10 mg b." | 1.28 | Oral pharmacokinetics of felodipine in patients with congestive heart failure: variable prediction using intravenous data. ( Dunselman, PH; Scaf, AH; Wesseling, H, 1989) |
| "Felodipine is a new calcium antagonist with a high degree of vascular selectivity." | 1.27 | Acute haemodynamic and metabolic effects of felodipine in congestive heart failure. ( Campbell, S; Jewitt, DE; Monaghan, MJ; Timmis, AD; Walker, L, 1984) |
| "Its potential role in the treatment of congestive heart failure was examined in short and long term oral studies." | 1.27 | Studies with felodipine in congestive heart failure. ( Jewitt, DE; Timmis, AD, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (44.26) | 18.7374 |
| 1990's | 28 (45.90) | 18.2507 |
| 2000's | 5 (8.20) | 29.6817 |
| 2010's | 1 (1.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braun, M | 1 |
| Edelmann, F | 1 |
| Knapp, M | 1 |
| Schön, S | 1 |
| Schwencke, C | 1 |
| Simonis, G | 1 |
| Borst, M | 1 |
| Weinbrenner, C | 1 |
| Strasser, RH | 1 |
| Drapkina, OM | 1 |
| Ashikhmin, IaI | 1 |
| Timmis, AD | 4 |
| Smyth, P | 2 |
| Kenny, JF | 2 |
| Campbell, S | 3 |
| Jewitt, DE | 4 |
| Kerkez, SA | 1 |
| Monaghan, MJ | 1 |
| Walker, L | 1 |
| Lanfranchi, J | 1 |
| de Vries, RJ | 2 |
| Queré, M | 1 |
| Lok, DJ | 1 |
| Sijbring, P | 1 |
| Bucx, JJ | 1 |
| van Veldhuisen, DJ | 2 |
| Dunselman, PH | 10 |
| Little, WC | 3 |
| Cheng, CP | 3 |
| Cohn, JN | 5 |
| Littler, WA | 4 |
| Sheridan, DJ | 1 |
| Dessì-Fulgheri, P | 1 |
| Paci, MV | 1 |
| Rappelli, A | 1 |
| Pettersson, K | 1 |
| Walton, T | 1 |
| Symes, LR | 1 |
| Elvelin, L | 1 |
| Nordlander, M | 1 |
| Boden, WE | 1 |
| Ziesche, S | 3 |
| Carson, PE | 1 |
| Conrad, CH | 1 |
| Syat, D | 1 |
| Scaf, AH | 7 |
| Wesseling, H | 6 |
| Russo, R | 1 |
| Rao, MA | 1 |
| Romano, M | 1 |
| Scotto di Santolo, M | 1 |
| Cardei, S | 1 |
| Giunta, A | 1 |
| Cuocolo, A | 1 |
| Volpe, M | 1 |
| Park, S | 1 |
| McCune, SA | 1 |
| Radin, MJ | 1 |
| Hoepf, TM | 1 |
| Hensley, J | 1 |
| Hohl, CM | 1 |
| Altschuld, RA | 1 |
| Smith, R | 1 |
| Anand, I | 1 |
| Dunkman, WB | 1 |
| Loeb, H | 1 |
| Cintron, G | 1 |
| Boden, W | 1 |
| Baruch, L | 2 |
| Rochin, P | 1 |
| Loss, L | 1 |
| White, CM | 1 |
| Zhang, W | 1 |
| Sun, X | 1 |
| Zhao, X | 1 |
| Thorén, P | 1 |
| Hedner, T | 1 |
| Anguita Sánchez, M | 1 |
| Wei, C | 1 |
| Burnett, JC | 1 |
| Wong, M | 2 |
| Germanson, T | 2 |
| Taylor, WR | 2 |
| Cohen, IS | 1 |
| Perry, G | 1 |
| Deedwania, P | 1 |
| Lopez, B | 1 |
| Smith, RF | 1 |
| Judd, D | 1 |
| Anand, IS | 1 |
| Terland, O | 1 |
| Todd, PA | 1 |
| Faulds, D | 1 |
| Kassis, E | 5 |
| Amtorp, O | 5 |
| Gradman, AH | 1 |
| Capewell, S | 1 |
| Wathen, CG | 1 |
| Muir, AL | 2 |
| Yedinak, KC | 1 |
| Lopez, LM | 1 |
| Cheng, TO | 1 |
| Agostoni, P | 1 |
| Doria, E | 1 |
| Riva, S | 1 |
| Polese, A | 1 |
| Nolan, J | 1 |
| van der Mark, TW | 1 |
| Kuntze, CE | 6 |
| van Bruggen, A | 4 |
| Hamer, JP | 2 |
| Lie, KI | 5 |
| Sweet, CS | 1 |
| Ludden, CT | 1 |
| Adkins, E | 1 |
| Seymour, AA | 1 |
| Emmert, S | 1 |
| Ribeiro, LG | 1 |
| Edgar, B | 2 |
| Tan, LB | 3 |
| Fox, Y | 1 |
| Binetti, G | 2 |
| Rubino, I | 1 |
| Varani, E | 1 |
| Spadoni, R | 1 |
| Ferretti, RM | 2 |
| Cervi, V | 1 |
| Magnani, B | 2 |
| Wessling, H | 1 |
| Kirch, W | 1 |
| Laskowski, M | 1 |
| Ohnhaus, EE | 1 |
| Aberg, J | 1 |
| Barbieri, L | 1 |
| Mestroni, L | 1 |
| Camerini, F | 1 |
| Pancaldi, S | 1 |
| Giovanelli, N | 1 |
| Negroni, S | 1 |
| Branzi, A | 1 |
| Specchia, S | 1 |
| Tweddel, AC | 3 |
| Martin, W | 2 |
| McGhie, AI | 2 |
| Hutton, I | 3 |
| Murray, RG | 2 |
| Waldorff, S | 2 |
| Fritz-Hansen, P | 1 |
| Rehnqvist, N | 1 |
| Billing, E | 1 |
| Moberg, L | 1 |
| Lundman, T | 1 |
| Olsson, G | 1 |
| Held, P | 1 |
| Swedberg, K | 1 |
| Emanuelsson, H | 1 |
| Hjalmarson, A | 1 |
| Holmberg, S | 1 |
| Waagstein, F | 1 |
10 reviews available for felodipine and Heart Failure
| Article | Year |
|---|---|
[Calcium antagonists and treatment of chronic heart failure].
Topics: Animals; Atrial Fibrillation; Calcium Channel Blockers; Dihydropyridines; Felodipine; Heart Failure; | 1995 |
Vascular versus myocardial effects of calcium antagonists.
Topics: Amlodipine; Animals; Dogs; Felodipine; Heart Failure; Hemodynamics; Humans; Muscle, Smooth, Vascular | 1994 |
Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Enalapril; Exercise; Felodipine; Heart Failure; | 1994 |
Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension.
Topics: Angina Pectoris; Animals; Drug Interactions; Felodipine; Heart Failure; Hemodynamics; Humans; Hypert | 1993 |
Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine.
Topics: Amlodipine; Calcium Channel Blockers; Coronary Disease; Felodipine; Heart Failure; Hemodynamics; Hum | 1995 |
Calcium channel blockers in left ventricular dysfunction or congestive heart failure.
Topics: Amlodipine; Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; Felodipine; Heart Failure | 1997 |
Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines.
Topics: Amlodipine; Calcium Channel Blockers; Dihydropyridines; Exercise Test; Exercise Tolerance; Felodipin | 2000 |
Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.
Topics: Angina Pectoris; Cardiomegaly; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Interact | 1992 |
Felodipine: a new dihydropyridine calcium-channel antagonist.
Topics: Angina Pectoris; Animals; Blood Pressure; Double-Blind Method; Felodipine; Heart Failure; Humans; Hy | 1991 |
[Calcium antagonists in congestive heart failure].
Topics: Calcium Channel Blockers; Cardiomyopathy, Dilated; Diltiazem; Felodipine; Heart Failure; Hemodynamic | 1988 |
30 trials available for felodipine and Heart Failure
| Article | Year |
|---|---|
The calcium channel blocker felodipine attenuates the positive hemodynamic effects of the beta-blocker metoprolol in severe dilated cardiomyopathy--a prospective, randomized, double-blind and placebo-controlled study with invasive hemodynamic assessment.
Topics: Adrenergic beta-Antagonists; Calcium Channel Blockers; Cardiomyopathy, Dilated; Double-Blind Method; | 2009 |
[Calcium channels blocker felodipin in the treatment of patients with arterial hypertension and chronic cardial failure with preserved cardiac output].
Topics: Blood Pressure; Calcium Channel Blockers; Cardiac Output; Chronic Disease; Diagnosis, Differential; | 2011 |
Comparison of effects on peak oxygen consumption, quality of life, and neurohormones of felodipine and enalapril in patients with congestive heart failure.
Topics: Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Double-Blind | 1995 |
Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Digoxin; Di | 1995 |
Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiotonic Agents; Chronic Dise | 1996 |
Relationship of changes in felodipine pharmacokinetics to haemodynamics during chronic oral treatment of congestive heart failure patients.
Topics: Administration, Oral; Calcium Channel Blockers; Double-Blind Method; Felodipine; Heart Failure; Hemo | 1995 |
Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Double-Blind Method; Enal | 1997 |
Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change.
Topics: Calcium Channel Blockers; Chronic Disease; Echocardiography, Doppler, Color; Felodipine; Heart Failu | 2000 |
Plasma norepinephrine and atrial natriuretic peptide in heart failure: influence of felodipine in the third Vasodilator Heart Failure Trial. V-HeFT III investigators.
Topics: Administration, Oral; Adolescent; Atrial Natriuretic Factor; Biomarkers; Cause of Death; Felodipine; | 2000 |
Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.
Topics: Angina Pectoris; Cardiomegaly; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Interact | 1992 |
Long-term clinical, hemodynamic, angiographic, and neurohumoral responses to vasodilation with felodipine in patients with chronic congestive heart failure.
Topics: Adult; Aged; Angiocardiography; Blood Cell Count; Catecholamines; Chronic Disease; Epinephrine; Felo | 1990 |
Short- and long-term controlled studies of felodipine in patients with congestive heart failure.
Topics: Double-Blind Method; Felodipine; Heart Failure; Humans; Pressoreceptors; Randomized Controlled Trial | 1990 |
Felodipine: a new dihydropyridine calcium-channel antagonist.
Topics: Angina Pectoris; Animals; Blood Pressure; Double-Blind Method; Felodipine; Heart Failure; Humans; Hy | 1991 |
Acute and chronic efficacy of felodipine in congestive heart failure.
Topics: Double-Blind Method; Felodipine; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Mal | 1991 |
Different results in cardiopulmonary exercise tests after long-term treatment with felodipine and enalapril in patients with congestive heart failure due to ischaemic heart disease.
Topics: Aged; Coronary Disease; Double-Blind Method; Drug Evaluation; Enalapril; Exercise Test; Felodipine; | 1990 |
Plasma concentration-effect relationship of felodipine intravenously in patients with congestive heart failure.
Topics: Aged; Blood Pressure; Cardiac Output; Clinical Trials as Topic; Double-Blind Method; Felodipine; Fem | 1989 |
Arterial vasodilator therapy in heart failure: haemodynamic response patterns predictive of changes in exercise capacity.
Topics: Aged; Cardiac Output; Double-Blind Method; Exercise; Exercise Test; Felodipine; Female; Heart Failur | 1989 |
Efficacy of felodipine in congestive heart failure.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Exercise Test; Felodipine; Female; Heart Failur | 1989 |
Effects of felodipine on plasma digoxin levels and haemodynamics in patients with heart failure.
Topics: Aged; Calcium Channel Blockers; Clinical Trials as Topic; Digoxin; Felodipine; Female; Heart Failure | 1989 |
Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure.
Topics: Administration, Oral; Aged; Calcium Channel Blockers; Cardiac Output; Clinical Trials as Topic; Doub | 1989 |
Cardiovascular and neurohumoral postural responses and baroreceptor abnormalities during a course of adjunctive vasodilator therapy with felodipine for congestive heart failure.
Topics: Aged; Cardiovascular System; Clinical Trials as Topic; Double-Blind Method; Epinephrine; Felodipine; | 1987 |
Digoxin-felodipine interaction in patients with congestive heart failure.
Topics: Aged; Clinical Trials as Topic; Digoxin; Double-Blind Method; Drug Interactions; Drug Therapy, Combi | 1988 |
Felodipine in patients with chronic heart failure: discrepant haemodynamic and clinical effects.
Topics: Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Echocardiography; Exercise Tes | 1987 |
Efficacy of felodipine in chronic congestive heart failure: a placebo controlled haemodynamic study at rest and during exercise and orthostatic stress.
Topics: Adult; Aged; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method; Felodipine; Fe | 1987 |
Felodipine in heart failure. A double-blind, randomised, placebo-controlled parallel-group study in 23 patients.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Felodipine; Heart Failure; H | 1987 |
Pharmacokinetics of felodipine and effect on digoxin plasma levels in patients with heart failure.
Topics: Aged; Antihypertensive Agents; Digoxin; Felodipine; Female; Heart Failure; Humans; Male; Middle Aged | 1987 |
Haemodynamic effects of felodipine during supine resting and exercising states and orthostatic tilt in patients with chronic congestive heart failure.
Topics: Antihypertensive Agents; Chronic Disease; Felodipine; Heart Failure; Hemodynamics; Humans; Nitrendip | 1987 |
An analytical method to separate inotropic and vasodilatory drug effects in patients with heart failure.
Topics: Aged; Cardiac Output; Cardiotonic Agents; Dobutamine; Felodipine; Female; Heart Failure; Heart Funct | 1987 |
Calcium channel blocker and isosorbide 5-mononitrate in the management of chronic cardiac failure.
Topics: Chronic Disease; Coronary Disease; Drug Therapy, Combination; Exercise Test; Felodipine; Heart Failu | 1987 |
Acute haemodynamic effects of felodipine in congestive heart failure.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Clinical Trials as Topic; Felodipine; Female; Heart Fai | 1985 |
23 other studies available for felodipine and Heart Failure
| Article | Year |
|---|---|
Effects of vasodilator treatment with felodipine on haemodynamic responses to treadmill exercise in congestive heart failure.
Topics: Adult; Aged; Antihypertensive Agents; Drug Evaluation; Felodipine; Female; Heart Failure; Heart Func | 1984 |
Restoration of normal reflex responses to orthostatic stress during felodipine therapy in congestive heart failure.
Topics: Adult; Aged; Felodipine; Female; Heart; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Nife | 1984 |
Acute haemodynamic and metabolic effects of felodipine in congestive heart failure.
Topics: Adult; Aged; Fatty Acids, Nonesterified; Felodipine; Glucose; Heart Failure; Hemodynamics; Humans; L | 1984 |
[The role of ACE inhibitors in heart failure. Lessons of CONSENSUS, SOLVD and V-HeFTII].
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Clinical | 1994 |
Effects of felodipine on left ventricular systolic and diastolic performance in congestive heart failure.
Topics: Animals; Diastole; Dogs; Felodipine; Heart Failure; Systole; Ventricular Function, Left | 1994 |
[Prospects of pharmacologic treatment of post-ischemic heart failure].
Topics: Calcium Channel Blockers; Felodipine; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial I | 1995 |
Verapamil accelerates the transition to heart failure in obese, hypertensive, female SHHF/Mcc-fa(cp) rats.
Topics: Animals; Blood Pressure; Brain; Calcium Channel Blockers; Felodipine; Female; Heart; Heart Failure; | 1997 |
Effects of calcium antagonist felodipine on renal sympathetic nerve activity in rats with congestive heart failure.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Felodipine; Heart; Heart Failure; Heart Rate; Kid | 1997 |
[Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1999 |
Inhibition by calcium antagonism of circulating and renal endothelin in experimental congestive heart failure.
Topics: Animals; Calcium Channel Blockers; Constriction, Pathologic; Dogs; Endothelins; Felodipine; Heart Fa | 2000 |
Treatment of chronic heart failure.
Topics: Chronic Disease; Felodipine; Heart Failure; Humans | 1992 |
Hemodynamic effects of the vascular selective calcium antagonist felodipine in patients with impaired left ventricular function.
Topics: Coronary Disease; Felodipine; Heart Failure; Hemodynamics; Humans; Hypertension; Myocardial Contract | 1992 |
Central and peripheral haemodynamic responses to felodipine in congestive heart failure.
Topics: Adult; Aged; Compliance; Felodipine; Heart Failure; Hemodynamics; Humans; Male; Middle Aged | 1991 |
All calcium channel blockers are not alike.
Topics: Amlodipine; Calcium Channel Blockers; Diltiazem; Felodipine; Heart Failure; Humans; Nifedipine | 1991 |
Modulation of venous tone in heart failure.
Topics: Captopril; Felodipine; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Milrinone; Phosp | 1991 |
Enalapril in experimental hypertension and acute heart failure: comparison with calcium channel blockers.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; D | 1986 |
Felodipine in severe chronic congestive heart failure: acute effects on central hemodynamics and regional blood flow distribution.
Topics: Adult; Aged; Blood Pressure; Chronic Disease; Felodipine; Heart Failure; Heart Rate; Hemodynamics; H | 1989 |
Oral pharmacokinetics of felodipine in patients with congestive heart failure: variable prediction using intravenous data.
Topics: Administration, Oral; Aged; Calcium Channel Blockers; Double-Blind Method; Felodipine; Female; Heart | 1989 |
Hemodynamic effects of felodipine in congestive heart failure.
Topics: Exercise; Felodipine; Heart Failure; Hemodynamics; Humans; Middle Aged | 1987 |
Sustained haemodynamic effects of felodipine in patients with chronic cardiac failure.
Topics: Adult; Blood Pressure; Exercise; Felodipine; Female; Heart Failure; Hemodynamics; Humans; Male; Midd | 1988 |
Haemodynamic effects of felodipine in congestive heart failure.
Topics: Adult; Aged; Antihypertensive Agents; Felodipine; Female; Heart Failure; Hemodynamics; Humans; Male; | 1987 |
Felodipine in ventricular dysfunction.
Topics: Adult; Cardiac Pacing, Artificial; Coronary Circulation; Coronary Disease; Exercise Test; Felodipine | 1986 |
Studies with felodipine in congestive heart failure.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Ech | 1985 |